[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340788-105":59,"doc-detail-340788-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","pcmt1-as-a-prognostic-marker-in-breast-cancer","PCMT1 as a prognostic marker in breast cancer","","Overexpression of PCMT1 is investigated as a prognostic marker for triple-negative breast cancer (TNBC), a highly aggressive subtype lacking ER, PR, and HER2. The study tests whether PCMT1 protein levels relate to overall survival and clinical progression. Using 64 TNBC patient samples analyzed by ImageJ with an IHC Profiler driver, and extending reliability with The Cancer Genome Atlas cohort, PCMT1 shows strong immunoreactivity and significant association with shorter survival.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pcmt1-as-a-prognostic-marker-in-breast-cancer/340788/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pcmt1-as-a-prognostic-marker-in-breast-cancer/340788.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the main aim of the study?","Question",{"text":113,"@type":114},"To determine the relationship between PCMT1 protein overexpression and prognosis, including patient survival, in triple-negative breast cancer.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were PCMT1 levels measured in the TNBC samples?",{"text":118,"@type":114},"PCMT1 expression was quantified by image analysis using ImageJ with the IHC Profiler driver.",{"name":120,"@type":111,"acceptedAnswer":121},"What prognostic effect did high PCMT1 expression show in TNBC?",{"text":122,"@type":114},"Patients with high PCMT1 expression had significantly lower overall survival than those with low PCMT1 expression, indicating shorter survival as a prognostic sign.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},340788,1790216852,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Clinical and Translational Oncology (2025) 27:1558–1568  \n[https://doi.org/10.1007/s12094-024-03695-y](https://doi.org/10.1007/s12094-024-03695-y)  \nPCMT1 as a prognostic marker in breast cancer  \nPatryk Rogaczewski1,2 · Michał Janiak1,2 · Jędrzej Borowczak1 · Łukasz Szylberg1,2  \nReceived: 14 May 2024 / Accepted: 22 August 2024 / Published online: 5 September 2024 © The Author(s) 2024  \nAbstract  \nIntroduction Triple-negative breast cancer (TNBC) is one of the most aggressive cancers in women, therefore it is necessary to determine novel prognostic markers to estimate survival and advancement the treatment of the disease. Recently, PCMT1, a protein mediating TNBC immune infiltration, has gained attention as a potential therapeutic target. The aim of the study was to demonstrate the relationship between PCMT1 protein overexpression as a prognostic indicator for patients with TNBC cancer and patient survival.  \nMaterials and methods The study included 64 samples collected from 64 TNBC patients. We used the ImageJ software with the IHC Profiler driver for image analysis. To improve the reliability of the results, we expanded the analysis by including The Cancer Genome Atlas cohort.  \nResults We observed strong PCMT1 immunoreactivity in breast cancer samples and PCMT1 expression in TNBC was significantly higher than in the control group. Patients with high PCMT1 expression had a significantly lower overall survival rate (60.62% vs. 90.35%, respectively) than patients with low PCMT1 expression. In our study and TCGA groups, PCMT1 expression did not correlate with lymph node involvement and distant metastases but correlated with tumor stage. The results obtained in a larger TCGA group are consistent with those in our research group. Overexpression of PCMT1 was a prognostic marker of shorter survival in patients with TNBC.  \nConclusions The overexpression of the PCMT1 protein in triple negative breast cancer significantly correlated with shorter overall survival. The confirmed association could be a potential prognostic biomarker for patients with TNBC.  \nKeywords PCMT1 · Cancer · Triple-negative breast cancer · Prognosis · Survival  \nIntroduction  \nBreast cancer accounts for 20–30% of all cancer cases in women and is the most often diagnosed malignancy in females [1] . Its subtype, called triple-negative breast cancer (TNBC), is characterized by the lack of human epidermal growth factor receptor 2 (HER2), estrogen receptors (ER) and progesterone receptors (PR), and accounts for a disproportionately high percentage of breast-cancer fatalities, while constituting only ~ 15% of all invasive cases [2] .  \n* Patryk Rogaczewski[pat.rogaczewski@gmail.com](pat.rogaczewski@gmail.com)  \n1 Department of Tumor Pathology and Pathomorphology, Oncology Centre in Bydgoszcz ul. Romanowska, Prof. Franciszek Łukaszczyk Memorial Hospital, 85-796 Bydgoszcz, Poland  \n2 Department of Obstetrics, Gynaecology and Oncology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland  \nTNBC continues to have a bad prognosis despite the fact that the treatment of patients with breast cancer has recently improved. TNBC is distinguished by significant intra-tumor heterogeneity, frequent acquisition of treatment resistance, and the lack of biomarkers, which make treatment difficult [3] .  \nProtein L-isoaspartate (D-aspartate) O-methyltransferase (PCMT1) type II, sometimes referred to as PIMT, is a repair enzyme that recognize and transform L-isoaspartyl and D-aspartyl by starting the process of converting aspartyl residues that have spontaneously isomerized back to their original form [4] . The human PCMT1 protein is a monomeric enzyme composed of two isoforms that were combined during alternative splicing [5] . PCMT1 has been linked to a number of RNA processing activities, such as controlling mRNA nuclear export to promote protein translation [6] . Cellular aging and microenvironmental stress are linked to spontaneous protein dea","cbCaio8IC0sZ2K8L","https://ap.wps.com/l/cbCaio8IC0sZ2K8L","pdf",1066517,"English","# Abstract\n# Introduction\n# Materials and methods\n## Clinicopathological data\n# Results\n# Conclusions","[{\"question\":\"What was the main aim of the study?\",\"answer\":\"To determine the relationship between PCMT1 protein overexpression and prognosis, including patient survival, in triple-negative breast cancer.\"},{\"question\":\"How were PCMT1 levels measured in the TNBC samples?\",\"answer\":\"PCMT1 expression was quantified by image analysis using ImageJ with the IHC Profiler driver.\"},{\"question\":\"What prognostic effect did high PCMT1 expression show in TNBC?\",\"answer\":\"Patients with high PCMT1 expression had significantly lower overall survival than those with low PCMT1 expression, indicating shorter survival as a prognostic sign.\"}]","PCMT1 as a prognostic marker in breast cancer | PDF",1790038907,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/30581434eda5aa9dac13812c8cc47810.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0f9080437b7dd6822a390b7a3b55a662.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a94669530edfba90ba94aef460ddf8b4.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/07e0b589948bc91cc9a2c27ba2cb9c91.webp",980,1301]